Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Globeflex Capital L P

Globeflex Capital L P raised its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 59.1% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 8,073 shares of the specialty pharmaceutical company’s stock after buying an additional 3,000 shares during the quarter. Globeflex Capital L P’s holdings in Jazz Pharmaceuticals were worth $994,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. CIBC Asset Management Inc raised its stake in shares of Jazz Pharmaceuticals by 5.2% during the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock valued at $243,000 after purchasing an additional 97 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 129 shares in the last quarter. Jones Financial Companies Lllp raised its stake in shares of Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 130 shares in the last quarter. Waterfront Wealth Inc. raised its stake in shares of Jazz Pharmaceuticals by 1.4% during the fourth quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company’s stock valued at $1,191,000 after purchasing an additional 137 shares in the last quarter. Finally, Ellsworth Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 0.4% during the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock valued at $4,675,000 after purchasing an additional 149 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Robert Iannone sold 2,403 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $138.41, for a total value of $332,599.23. Following the transaction, the chief marketing officer now owns 79,621 shares of the company’s stock, valued at approximately $11,020,342.61. This trade represents a 2.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock worth $4,022,825 over the last three months. 4.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on JAZZ shares. Royal Bank of Canada lowered their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Piper Sandler reaffirmed an “overweight” rating and set a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. JPMorgan Chase & Co. lifted their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Finally, Barclays reissued an “overweight” rating and issued a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Buy” and an average target price of $190.53.

Jazz Pharmaceuticals Stock Up 1.4 %

JAZZ opened at $137.96 on Friday. The business has a 50 day moving average price of $129.52 and a 200 day moving average price of $120.76. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market cap of $8.38 billion, a P/E ratio of 19.43, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.